Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis

International Journal of Clinical Practice

Volumn 52, Issue 5, 1998, Pages 289-297

  Langan, C ^a   Clecner, B ^b   Cazzola, C M ^c,d   Brambilla, C ^f   Holmes, C Y ^e   Staley, H ^e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Hosp Hotel Dieu de St Jerome   (Canada)

^c Settore Farmacol Clin Respiratoria   (Italy)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Glaxo Wellcome R and D Ltd ^*

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; MACROLIDE;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRONCHITIS; CEFUROXIME; CEPHALOSPORINS; CHRONIC DISEASE; CLARITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031821866     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Staley H, McDade HB, Paes D. Is an objective assessment of antibiotic therapy in exacerbation of chronic bronchitis possible? J Antimicrob Chemother 1993; 31: 193-197.
2. Verbist L. What and where are the pathogens? Clinical significance of antibiotic tissue concentrations. Res Clin Forums 1990; 12: 9-14.
3. Brambilla C, Kastanakis S, Knight S. Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992; 11: 118-124.
4. Ginsburg CM, McCracken GH Jr, Petruska L, Olsen K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985; 28: 504-507.
5. Marx MA, Fant WK, Cefuroxime axetil. Drug Intel Clin Pharm 1988; 22: 651-658.
6. Dellamonica P. Cefuroxime axetil. Int J Antimicrob Agents 1994; 4: 23-36.
7. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-164.
8. Piscitelli DC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11: 137-152.
9. Fraschini F, Scaglione F, Pintucci G et al. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother 1991; 27(suppl A): 61-65.
10. Winter J, Dhillon P. Penetration of cefuroxime into bronchial mucosa following oral administration of cefuroxime axetil. J Antimicrob Chemother 1991; 27: 556-558.
11. Begg C, Mildred C, Eastwood S et al. Improving the quality of report ing of randomised clinical trials. The CONSORT Statement. JAMA 1996; 276(8): 637-639.
12. Beam TR Jr, Gilbert DN, Kunin CM, Eds. Guidelines for the clinical evaluation of anti-infective drugs. European Society of Clinical Microbiology and Infectious Diseases, 1993.
13. Stokes EJ, Waterworth PM. Antibiotic sensitivity tests by diffusion methods. Association of Clinical Pathologists Broadsheet 1972.
14. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-39.
15. Ball P, Harris JM, Lowson D et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-68.